Medpace Holdings, INC Form 4 insider transactions

Director Robert O. Kraft reports the vesting of restricted stock units into Medpace Holdings common stock.

Director Brian T. Carley reported the vesting and conversion of restricted stock units into Medpace Holdings, Inc. common stock.

Susan Burwig, Executive VP of Operations at Medpace Holdings, sold 7,681 shares of common stock on June 5, 2024.

August J. Troendle, CEO of Medpace Holdings, reported the sale of company stock in two transactions on May 24 and May 28, 2024.

August J. Troendle, CEO of Medpace Holdings, reported selling 55 shares of common stock at $400 per share on May 22, 2024.

Medpace Holdings CEO August J. Troendle sold 4,020 shares of common stock at a weighted average price of $400.19 on May 20, 2024.

Cornelius P. McCarthy III, a director of Medpace Holdings, Inc., acquired stock options on May 17, 2024.

Director Ashley M. Keating acquired stock options in Medpace Holdings, Inc. on May 17, 2024.

Director Femida H. Gwadry-Sridhar acquired stock options in Medpace Holdings, Inc. on May 17, 2024.

Robert O. Kraft, a director at Medpace Holdings, Inc., acquired stock options on May 17, 2024.

Director Brian T. Carley of Medpace Holdings, Inc. reports acquisition of stock options.

Director Fred B. Davenport Jr. of Medpace Holdings, Inc. reports the acquisition of stock options.

Medpace Holdings CEO August J. Troendle sold shares of the company's common stock on May 15 and 16, 2024, according to a Form 4 filing with the SEC.

Medpace Holdings CEO August J. Troendle reported the sale of 4,956 shares of common stock at a weighted average price of $402.89 on May 10, 2024.

Medpace Holdings CEO August J. Troendle reported the sale of company stock in two transactions on May 8 and May 9, 2024.

Medpace Holdings CEO August J. Troendle reports selling shares of the company's common stock on May 6th and 7th, 2024.

Medpace Holdings CEO August J. Troendle reports selling shares of common stock on May 1st and 2nd, 2024.

Medpace Holdings CEO August J. Troendle reports selling shares of common stock on April 29 and April 30, 2024.

Robert O. Kraft, a director at Medpace Holdings, exercised stock options on March 31, 2024, acquiring 72 shares of common stock.

Cornelius P. McCarthy III, a director at Medpace Holdings, exercised stock options on March 31, 2024, resulting in the acquisition of 63 shares of common stock.

Brian T. Carley, a director at Medpace Holdings, exercised stock options on March 31, 2024, resulting in the acquisition of 79 shares of common stock.

Susan Burwig, Executive VP of Operations at Medpace Holdings, sold 102 shares of common stock on March 15, 2024.

Ashley M. Keating, a director at Medpace Holdings, exercised stock options and sold shares on March 14, 2024.

Medpace Holdings CEO August J. Troendle sold 200,000 shares of common stock over three days in March 2024, through Medpace Investors, LLC.

Medpace Investors, LLC, a 10% owner of Medpace Holdings, Inc., sold 200,000 shares of common stock over three days in early March.

Director Ashley M. Keating exercised stock options and sold shares of Medpace Holdings, Inc. on March 7, 2024.

Medpace Holdings President Jesse Geiger exercised stock options and sold shares on March 4th and 5th, 2024, according to a Form 4 filing with the SEC.

Medpace Holdings CEO August J. Troendle sold 100,000 shares of common stock in two separate transactions on March 4th and 5th, 2024, at weighted average prices of $403.12 and $402.70, respectively.

Medpace Investors, LLC, a 10% owner of Medpace Holdings, Inc., sold 100,000 shares of common stock over two days in March 2024.

Medpace Investors, LLC, a 10% owner of Medpace Holdings, Inc., sold 100,000 shares of common stock in two transactions on February 29, 2024, and March 1, 2024.